7 active not recruiting, 5 completed, 4 not yet recruiting, 4 recruiting. 19 Phase 2, 4 Phase 1, 4 Phase 3, 1 Early Phase 1, 1 Phase 4.
Follow Platinum-based chemotherapy: new trials by email Literature Review of Platinum-based chemotherapy trials Research Report on Platinum-based chemotherapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Firmonertinib Plus Chemotherapy for Unresectable EGFR PACC-Mutant Stage III Lung Cancer: A Phase II Study Firmonertinib, Platinum-based chemotherapy - Lung Adenocarcinoma, Stage III Lung Cancer | Phase 2 | Not yet recruiting | Hunan Province Tumor Hospital | 27 | 2026-11-01 | 2026-10-16 |
| Trastuzumab Rezetecan Plus Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer Trastuzumab Rezetecan (SHR-A1811), Bevacizumab, Platinum-based chemotherapy - Ovarian Cancer, Fallopian Tube Cancers | Phase 2 | Not yet recruiting | Peking University Cancer Hospital & Institute | 53 | 2026-10-22 | 2026-10-01 |
| Neoadjuvant Chemoradiotherapy Versus Neoadjuvant Immunochemotherapy for Resectable Esophageal Cancer: A Target Trial Emulation Study Radiotherapy, Platinum-based Chemotherapy, PD-1 Inhibitor - Esophageal Squamous Cell Carcinoma (ESCC) | Not yet recruiting | Henan Cancer Hospital | 400 | 2026-08-20 | 2026-08-21 | |
| Toripalimab Combined With Platinum-based Chemotherapy With or Without H1 Receptor Antagonist in the Perioperative Treatment of Resectable Non-small Cell Lung Cancer Toripalimab (240mg day1, Q3W*3cycle), Diphenhydramine, Platinum-based chemotherapy - NSCLC | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 120 | 2026-06-30 | 2026-06-12 |
| BRIDGE Study: Neoadjuvant Finotonlimab, Cetuximab, and Docetaxel in Resectable Recurrent HNSCC After Immunotherapy Progression Finotonlimab, Cetuximab, Docetaxel - Recurrent Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer | Phase 2 | Enrolling by invitation | Sun Yat-sen University | 42 | 2026-04-20 | 2026-06-01 |
| A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC) Cemiplimab, Platinum-based chemotherapy, REGN7075 - Non-Small Cell Lung Cancer | Phase 2 | Active not recruiting | Regeneron Pharmaceuticals | 120 | 2024-11-18 | 2026-08-24 |
| A Trial of AN0025 With Chemoradiation Therapy in Stage III NSCLC Participants AN0025 - Lung Cancer Stage III | Phase 1 | Withdrawn | Rutgers, The State University of New Jersey | 2024-11-01 | 2025-04-16 | |
| A Study of Adebrelimab in Combination with Chemo with or Without Bevacizumab Neoadjuvant Therapy for Resectable NSCLC Adebellizumab, Bevacizumab, Platinum-based chemotherapy - Resectable Lung Non-Small Cell Carcinoma | Phase 2 | Recruiting | The First Affiliated Hospital of Guangzhou Medical University | 60 | 2024-09-24 | 2025-01-15 |
| Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP) Camrelizumab, Thalidomide 50mg, Thalidomide 100mg - Lung Cancer, Nonsmall Cell, Esophageal Carcinoma | Phase 2 | Unknown | Henan Cancer Hospital | 132 | 2024-01-19 | 2024-03-29 |
| Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT) furmonertinib 240 mg oral, daily, furmonertinib 160 mg oral, daily, platinum-based chemotherapy - Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer | Phase 3 | Active not recruiting | ArriVent BioPharma, Inc. | 398 | 2023-06-01 | 2025-06-22 |
| Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma Serplulimab and Bevacizumab injection - Lung Adenocarcinoma, Stage IV Non-small Cell Lung Cancer | Phase 2 | Unknown | Fujian Cancer Hospital | 50 | 2023-01-10 | 2023-01-09 |
| A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors BAY2965501, Pembrolizumab, Platinum-based Chemotherapy - Advanced Solid Tumors | Phase 1 | Active not recruiting | Bayer | 284 | 2022-11-04 | 2026-07-07 |
| An Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europe Cemiplimab, Platinum-based chemotherapy - Non-small Cell Lung Cancer | Recruiting | Regeneron Pharmaceuticals | 500 | 2022-10-26 | 2026-10-21 | |
| HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy Patritumab Deruxtecan, Platinum-based chemotherapy - Nonsquamous Non-small Cell Lung Cancer, EGFR L858R | Phase 3 | Active not recruiting | Daiichi Sankyo | 586 | 2022-07-08 | 2026-08-27 |
| Study of Nivolumab-Ipilimumab and cfDNA in Lung Cancer cfDNA blood test, Nivolumab, Ipilimumab - Non Small Cell Lung Cancer | Phase 2 | Terminated | University Health Network, Toronto | 5 | 2022-01-24 | 2026-01-08 |
| Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib quaratusugene ozeplasmid, osimertinib, Platinum-Based Chemotherapy - Carcinoma, Non-Small Cell Lung | Phase 1 / Phase 2 | Recruiting | Genprex, Inc. | 158 | 2021-09-03 | 2026-09-16 |
| NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer and in Combination With Temozolomide in High-grade Glioma NTX-301, Platinum-based Chemotherapy, Temozolomide - Advanced Solid Tumor, Platinum-Resistant Ovarian Cancer | Phase 1 / Phase 2 | Terminated | Xennials Therapeutics Australia Pty Ltd | 12 | 2021-08-25 | 2022-12-20 |
| Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical Cancer camrelizumab； famitinib malate, platinum-based chemotherapy - Cervical Cancer | Phase 3 | Active not recruiting | Jiangsu HengRui Medicine Co., Ltd. | 443 | 2021-07-23 | 2025-09-09 |
| Ocular Conservative Treatment for Retinoblastoma : Efficacy of the New Management Strategies and Visual Outcome Melphalan or Melphalan + Topotecan, etoposide, carboplatin and vincristine or local ophthalmological treatment without IV chemotherapy, Carboplatin administered on Day 1 - Retinoblastoma | Phase 2 / Phase 3 | Recruiting | Institut Curie | 225 | 2021-03-25 | 2025-11-28 |
| Neoadjuvant PD-1 Antibody Plus Apatinib or Chemotherapy for Non-small Cell Lung Cancer Camrelizumab - Non Small Cell Lung Cancer | Phase 2 | Active not recruiting | Shanghai Pulmonary Hospital, Shanghai, China | 89 | 2020-07-26 | 2023-12-06 |
Showing 20 of 29. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (13) · Lung Neoplasms (5) · Ovarian Neoplasms (4) · Adenocarcinoma of Lung (2) · Esophageal Neoplasms (2) · Fallopian Tube Neoplasms (2) · Carcinoma, Renal Cell (1) · Carcinoma, Squamous Cell (1) · Esophageal Squamous Cell Carcinoma (1) · Glioma (1) · Head and Neck Neoplasms (1) · Melanoma (1) · Parkinson Disease 4, Autosomal Dominant Lewy Body (1) · Retinoblastoma (1) · Squamous Cell Carcinoma of Head and Neck (1)
Henan Cancer Hospital (2) · Hoffmann-La Roche (2) · Regeneron Pharmaceuticals (2) · University Health Network, Toronto (2) · ArriVent BioPharma, Inc. (1) · Bayer (1) · Daiichi Sankyo (1) · Fujian Cancer Hospital (1) · Fujian Medical University (1) · Genprex, Inc. (1) · Hunan Province Tumor Hospital (1) · Incyte Corporation (1) · Institut Curie (1) · Jiangsu HengRui Medicine Co., Ltd. (1) · New Mexico Cancer Research Alliance (1)
China (14) · Spain (9) · United States (8) · France (7) · United Kingdom (7) · Australia (6) · Canada (6) · Italy (5) · Taiwan (5) · Germany (4) · Israel (4) · South Korea (4) · Austria (3) · Belgium (3) · Brazil (3)
Adrian Sacher, M.D. (1) · Amit Oza, M.D. (1) · Changming Huang, Professor (1) · Chunyan Chen, MD, PhD (1) · Dennie V Jones, MD (1) · Gordon Jayson, MD, Prof. (1) · Jianxing He (1) · Joyce L. Steinberg, MD (1) · Lance Leopold, MD (1) · Mark S. Berger, MD (1) · Morgan Lam (1)
PMID 10089184, PMID 11091234, PMID 11223832, PMID 11289756, PMID 11712875, PMID 11754382, PMID 1334988, PMID 15783049, PMID 16003309, PMID 16643334, PMID 17058319, PMID 18095269, PMID 18656040, PMID 18685899, PMID 20113944, PMID 20610241, PMID 20650686, PMID 21336514, PMID 21573742, PMID 22752074, PMID 23018280, PMID 24399492, PMID 24826062, PMID 37689979, PMID 38095056, PMID 38980664, PMID 39054462, PMID 39892382, PMID 40682106, PMID 8180768
2023 (3), 2017 (1)